Gallen, Switzerland). BALB/c and BALB/c Thy1.1 mice were obtained from Charles River (Germany) and CD4-deficient BALB/c mice were obtained from Jackson Laboratories (USA). Mice deficient for the IFNGR [45], IL-6 [46], and IL-17A [47] mice were backcrossed on the BALB/c background for at least ten times.

Splenic CD4+ effector Th cells were obtained from Gefitinib mouse peptide-immunized mice at the peak of disease on day 21 post immunization [48] and restimulated in vitro for 2 days with 10 μg/mL myhca614–629 peptide and 50 U/mL IL-2. BW 5147 lymphoma cells (kindly provided by Dr. Annette Oxenius, ETH Zürich) were fused to antigen-stimulated splenocytes using polyethylene glycol 1500 (PEG 1500; Roche) following the manufacturer’s instructions. Following the substitution of hypoxanthin-aminopterin-thymidine (HAT; Gibco) selection medium, antigen specificity was assessed by ELISPOT assay [48], and positive clones were monoclonolized by limiting dilution. RNA isolation from myhca614–629-specific hybridoma cells was performed using TRIzol (Invitrogen) following the manufacturer’s instructions. cDNA synthesis was performed using Super Script II Reverse Transcriptase (Invitrogen) and oligo (dT) primers. The TCR V LY2157299 supplier genes were analyzed by flow cytometry and RT-PCR using previously published primer pairs [49]]. The DNA sequence of the myhca614–629-specific TCR was analyzed by PCR sequencing

and sequence alignment using the ImMunoGeneTics information system database (http://www.imgt.org). The TCR variable regions

(Vα-2J42; Vβ-8D-1J2–4) were cloned into TCR cassette vectors [50] using the following PCR primers: α-chain: 5′-ATTACCCGGGGCTTCAGTCTAGGAAGAATGGACACG-3′; 5′-ATTAGCGGCCGCCTTTAACACTTACTTGATTTAACAGAG-3′; β-chain: 5′-ATTACTCGAGCCTGCCTTAGTTCTGAGATGGGC-3′; 5′-ATTACCGCGGCTATACCCCAGCTTACCTAGCACCG-3′. Linearized constructs were injected at an equimolar ratio into fertilized oocytes of the CB6F1xBALB/c background and founder lines were backcrossed to BALB/c. TCR-M mice were kept heterozygous and cAMP nontransgenic littermates were used as controls. For histological analysis, hearts were fixed in 4% formaldehyde (formafix) for at least 12 h and embedded in paraffin. Histopathological changes were evaluated following hematoxilin/eosin and Elastica van Giesson (EVG) staining. Myocarditis severity was evaluated using a semiquantitative scoring system: 0, no inflammation; 1, <100 inflammatory cells involved, small inflammatory lesions; 2, >100 inflammatory cells involved, larger inflammatory lesions; 3, >10% of the heart section involved in inflammation; 4, >30% of the heart section involved in inflammation; 5, >30% of the heart section involved in inflammation with extensive fibrosis and dilation of ventricle. Images from heart sections were acquired using a Leica DMRA microscope and processed using Adobe Photoshop (Adobe Systems). In vivo neutralization of IL-17A was done with the anti-mouse IL-17A monoclonal antibody BZN035 (IgG2a).